Systematic review and meta-analysis of the efficacy and safety of therapy with @entity5136 containing regimens in the treatment of multidrug-resistant and extensively XXXX .

@entity1 @entity6371 @entity417 @entity5295 @entity1897 @entity5136
BACKGROUND: @entity5136 containing regimens have been proposed as potentially valuable alternatives for the treatment of @entity1 with @entity6371 ( @entity6371 ) or extensively @entity5295 ( @entity5295 ). METHODS: A systematic review and meta-analysis was conducted to assess the efficacy, safety and tolerability of @entity5136 for @entity5295 ( @entity5295 ) treatment. We searched the Cochrane Controlled Trial Registry, PubMed, Embase, Science Citation Index Expanded (SCI) and China National Knowledge Infrastructure (CNKI), database up to May 2014 to identify studies providing data of the use of @entity5136 for the treatment of @entity5295 . RESULTS: The search yielded 15 studies (367 @entity1 ) including one randomized controlled trial (RCT), covering 239 @entity1 who could be evaluated for effectiveness; 83% [95% confidence interval (CI), 75-90%; I(2)=62.8%] had a favorable outcome, defined as either cure or treatment completion. The pooled rate of culture conversion was 89% (95% CI, 83-95%; I(2)=49.6%). Between the group receiving daily @entity5136 doses of  <=600 or >600 mg, the mortality was considerably lower in @entity1 treated with less than 600 mg/day (P value <0.001). Of 367 @entity1 for whom data on safety was available, @entity1897 (31%, 95% CI, 19-42%; I(2)=81.7%) and @entity417 (25%, 95% CI, 15-34%; I(2)=76.6%) were the main adverse effects. @entity1 receiving less than 600 mg/day were more likely to experience nervous system adverse events (P value <0.01). CONCLUSIONS: The available evidence suggests that @entity5136 could be considered as a promising option as treatment of MDR/XDR @entity5295 . Randomized trials are warranted to define the dose and frequency of administration.
